Search
for

    Sort by

    Community Join

    990-1000 / 1000+ results

      community What’s more reliable right now, pyrilutamide or RU?

      in Treatment  15 upvotes 3 years ago
      Treatments for hair loss, with the user considering Pyrilutamide and RU58841 as options. It is noted that although Pyrilutamide has been studied more and is allegedly more effective, there are doubts about its authenticity in the market. KX-826 is suggested as an alternative as it has a stronger effect than RU58841 and there is scientific research on it.

      community Pyrilutamide/KX-826 for women?

      in Treatment  1 upvotes 1 year ago
      Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.

      community Shiseido (RepliCel) likely to cost around $1000

       4 upvotes 10 years ago
      RepliCel's potential hair loss treatment may cost around $1000 and aims to protect hair follicles from DHT, possibly reversing some miniaturization. It is not considered a cure and may be most effective in early hair loss stages, with its main advantage over finasteride being the lack of sexual side effects.

      community Breezula phase 3 results said to be released next month

      in Product  27 upvotes 1 year ago
      Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

      community No side effects on pyrilutamide / KX-826 so far

      in Research/Science  207 upvotes 4 years ago
      User TopBack56 and friends tried pyrilutamide (KX-826) for hair loss without experiencing negative side effects. They observed fine vellus hairs but no thick hair growth yet, and plan to add GT20029 to their regime after safety trials.